方智芸,瞿斯文,张津铭,王伟国,阙扬铭,莫娟芬,沈海燕

• 1:嘉兴市第二医院消化内科
• 2:嘉兴市第二医院中心实验室

摘要(Abstract)：

目的 探讨乌司奴单抗对炎症性肠病（IBD）患者高凝状态及结肠微循环的影响。方法IBD患者60例分为克罗恩病组（CD组，30例）和溃疡性结肠炎组（UC组，30例），另设非IBD患者为对照组（C组，30例）。CD组和UC组采用首次静脉注射和2次皮下注射乌司奴单抗治疗。比较三组炎症标志物、凝血功能指标、纤溶酶原激活剂抑制剂-1(PAI-1)和凝血酶激活纤溶抑制剂（TAFI）水平。行结肠镜检查比较CD组和UC组治疗前后内镜活动度评分。行免疫组化染色比较三组结肠黏膜组织中PAI-1和整合素_β-3(ITGB3)阳性指数。结果 与C组比较，CD组和UC组治疗前血清超敏CRP(hsCRP)、ESR、IFN-γ、D-D、PAI-1及TAFI水平、血浆纤维蛋白原（Fib）水平以及结肠黏膜组织中PAI-1和ITGB3阳性指数升高，而Hb水平降低（P<0.05）。与治疗前比较，CD组和UC组治疗后血清hsCRP、ESR、IFN-γ、D-D、PAI-1及TAFI水平、血浆Fib水平、内镜活动度评分以及结肠黏膜组织中PAI-1和ITGB3阳性指数均降低，而Hb水平升高（P<0.05）。结论 乌司奴单抗可以缓解IBD患者的高凝状态，改善结肠微循环。

关键词(KeyWords)： 炎症性肠病;乌司奴单抗;纤溶酶原激活剂抑制剂-1;凝血酶激活纤溶抑制剂

Abstract:

Keywords:

基金项目(Foundation): 嘉兴市科技计划项目（2022AD30007、2024AD30082）

作者(Author): 方智芸,瞿斯文,张津铭,王伟国,阙扬铭,莫娟芬,沈海燕

DOI: 10.19460/j.cnki.0253-3685.2025.09.010

参考文献(References)：

• [1]HODSON R.Inflammatory bowel disease[J].Nature,2016,540(7634):S97.
• [2]GALA D,NEWSOME T,ROBERSON N,et al.Thromboembolic events in patients with inflammatory bowel disease:a comprehensive overview[J].Diseases,2022,10(4):73.
• [3]MAGRO F,SOARES J B,FERN ANDES D.Venous thrombosis and prothrombotic factors in inflammatory boweldisease[J].World J Gastroenterol,2014,20(17):4857-4872.
• [4] MEDCALF R L,KERAGALA C B.The fibrinolytic system:mysteries and opportunities[J].Hemasphere,2021,5(6):e570.
• [5]HEO C M,KIM T J,KIM E R,et al.Risk of venous thromboembolism in Asian patients with inflammatory bowel disease:a nationwide cohort study[J].Sci Rep,2021,11(1):2025.
• [6]中华医学会消化病学分会炎症性肠病学组,钱家鸣,吴开春.炎症性肠病诊断与治疗的共识意见(2018年,北京)[J].中华消化杂志,2018,38(5):292-311.
• [7]中国炎症性肠病诊疗质控评估中心,中华医学会消化病学分会炎症性肠病学组.生物制剂治疗炎症性肠病专家建议意见[J].胃肠病学,2022,27(10):601-614.
• [8]UNGARO R C,JORDAN R,YZET C,et al.Su1912 CDEIS score of 2 is optimal cut-off associated with lower risk of disease progression in early Crohn's disease:data from the calm study[J].Gastroenterology,2020,158(6):699.
• [9]CHEUNG V T F,GUPTA T,OLSSON-BROWN A,et al.Immune checkpoint inhibitor-related colitis assessment and prognosis:can IBD scoring point the way?[J].Br J Cancer,2020,123(2):207-215.
• [10]LUYENDYK J P,SCHOENECKER J G,FLICK M J.The multifaceted role of fibrinogen in tissue injury and inflammation[J].Blood,2019,133(6):511-520.
• [11]ROGLER G,SINGH A,KAVANAUGH A, et al.Extraintestinal manifestations of inflammatory bowel disease:current concepts,treatment,and implications for disease management[J].Gastroenterology,2021,161(4):1118-1132.
• [12]HOZUMI H,RUSSELL J,VITAL S,et al.IL-6 mediates the intestinal microvascular thrombosis associated with experimental colitis[J].Inflamm Bowel Dis,2016,22(3):560-568.
• [13]KERAGALA C B, MEDCALF R L.Plasminogen:an enigmatic zymogen[J].Blood,2021,137(21):2881-2889.
• [14]HAYASHI Y,NAKASE H.The molecular mechanisms of intestinal inflammation and fibrosis in Crohn's disease[J].Front Physiol,2022,13:845078.
• [15]JóJáRT B,RESáL T,KATA D,et al.Plasminogen activator inhibitor 1 is a novel faecal biomarker for monitoring disease activity and therapeutic response in inflammatory bowel diseases[J].J Crohns Colitis,2024,18(3):392-405.
• [16]BADESHA A S,TAMBER K K,POWEZKA K,et al.Management of acute iliofemoral deep venous thrombosis in inflammatory bowel disease:transitioning from conservativemanagement to early intervention[J].Cureus,2021,13(8):e17426.
• [17]KAIKO G E,CHEN F,LAI C W,et al.PAI-1 augments mucosal damage in colitis[J].Sci Transl Med,2019,11(482):eaat0852.
• [18]WANG X,GUO L,HUANG J,et al.Plasminogen activator inhibitor-1 potentiates neutrophil infiltration and tissue injury in colitis[J].Int J Biol Sci,2023,19(7):2132-2149.
• [19]SILLEN M,DECLERCK P J.Thrombin activatable fibrinolysis inhibitor(TAFI):an updated narrative review[J].Int J Mol Sci,2021,22(7):3670.
• [20]OWCZAREK D,UNDAS A,FOLEY J H,et al.Activated thrombin activatable fibrinolysis inhibitor(TAFIa)is associated with inflammatory markers in inflammatory bowel diseases TAFIa level in patients with IBD[J].J Crohns Colitis,2012,6(1):13-20.
• [21]YüZBASIOGLU B, USTAOGLU M,YüZBASIOGLU S,et al.Levels of TAFI,TFPI and ADAMTS-13 in inflammatory bowel disease[J].Turk J Gastroenterol,2019, 30(12):1025-1029.
• [22]VUYYURU S K,SHACKELTON L M,HANZEL J,et al.Targeting IL-23 for IBD:rationale and progress to date[J].Drugs,2023,83(10):873-891.
• [23]BEYAZIT Y,SAYILIR A,TANOGLU A,et al.Plasma thrombin-activatable fibrinolysis inhibitor levels correlate with the disease activity of ulcerative colitis[J].Intern Med,2016,55(14):1831-1836.
• [24]MOSCHEN A R,TILG H,RAINE T.IL-12,IL-23 and IL-17in IBD:immunobiology and therapeutic targeting[J].Nat Rev Gastroenterol Hepatol,2019,16(3):185-196.
• [25]LUTHER N,SHAHNEH F,BR?HLER M,et al.Innate effector-memory T-cell activation regulates post-thrombotic vein wall inflammation and thrombus resolution[J].Circ Res,2016,119(12):1286-1295.
• [26]SU Z,LU H,JIANG H,et al.IFN-γ-producing Th 1 7 cells bias by HMGB1-T-bet/RUNX3 axis might contribute to progression of coronary artery atherosclerosis[J].Atherosclerosis,2015,243(2):421-428.
• [27]HAASNOOT M L,MOOKHOEK A,DUIJVESTEIN M,et al.Prognostic value of colonic tissue and blood eosinophils in ulcerative colitis[J].Inflamm Bowel Dis,2023,29(1):62-69.